Consistently, a drug sensitivity prediction analysis using the genomics of drug sensitivity in cancer database found that the sensitivity of OTUD6B‐knockdown cells to ATRA was likely to be significantly lower than that of control cells (Figure 6I). This evidence concerns the gene OTUD6B and cancer.